NASDAQ:FDMT
4D Molecular Therapeutics, Inc. Stock News
$25.34
-0.300 (-1.17%)
At Close: May 17, 2024
EMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
08:00am, Tuesday, 23'rd Jan 2024
EMERYVILLE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
01:01pm, Friday, 19'th Jan 2024
4D Molecular Therapeutics, Inc. (FDMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
08:00am, Thursday, 04'th Jan 2024
EMERYVILLE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
08:01am, Wednesday, 03'rd Jan 2024
EMERYVILLE, Calif. and CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), a leading clinical-stage genetic medicines company focused on unlocking the
EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next ge
4DMT to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 15'th Nov 2023
EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generatio
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
08:00am, Wednesday, 25'th Oct 2023
EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted nex
4D Molecular Therapeutics: Some Failures, A Few Key Successes
12:19pm, Monday, 25'th Sep 2023
4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions in patients. The company has five product candida
4DMT to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 07'th Sep 2023
EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for gen
4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance
11:19am, Monday, 10'th Jul 2023
4D Molecular Therapeutics demonstrates a robust economic position and promising line-up of gene therapies, with a commitment to innovation and strategic financial management. The company's financials
4D Molecular Therapeutics: A Complicated Story
10:15am, Friday, 07'th Jul 2023
Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. The company's approach to AAV de
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Thursday, 01'st Jun 2023
EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic me
Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics
05:57pm, Friday, 12'th May 2023
Viking Global Investors LP, the firm managed by Andreas Halvorsen (Trades, Portfolio), disclosed in a regulatory filing that it boosted its holding in 4D Molecular Therapeutics ( FDMT , Financial) in
4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?
07:39am, Monday, 08'th May 2023
4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into fu
